is commonly employed as the initial DMARD used for treatment of Rheumatoid arthritis [RA]. We aimed to contribute to the safety profile of MTX by assessing its cumulative effect on renal filtration. Fifty two RA adult females with normal base-line serum creatinine and GFR at the initial diagnosis of the disease were included. Group-1 [G1] included 30 patients [mean age 40.4 ± 4.4 years] on MTX and NSAIDS, while 22 RA patients [mean age 38.5 ± 8.2 years] who received NSAIDs only served as the control group [G2]. Renal function was assessed by GFR-measurement using Technetium diethylenetriamine-pentaacetic acid [Tc-99 m-DTPA] at the point of the study time corresponding to disease duration. 21/30 [70%] in G1 showed reduced GFR compared to 6/22 [27.3%] in G2 [P0.007] with 3.3 ± 0.5% annual reduction of GFR. Reduced GFR in G1 showed significant negative correlation with age [r = À0.396, P = 0.005], MTX-cumulative dose [r = À0.263, P = 0.049], MTX-intake duration [r = À0.293, P = 0.031] and NSAID-intake duration [r = À0.344, P = 0.014]. Low dose MTX has a slow cumulative effect on renal filtration manifested by GFR reduction over time that could be monitored by Tc-99 m DTPA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder with a prevalence of about 0.5-1% of the world population [1] . A variety of renal disorders can occur in RA patients due to the underlying disease, drugs used in treatment, or concurrent renal disease [2] .
Methotrexate (MTX) is commonly employed as the initial disease modifying anti-rheumatic drug (DMARD) for treatment of RA either as monotherapy or as ''anchor drug'' in combination with other DMARDs or anti-tumor necrosis factor agents [3] . Significant nephrotoxicity due to MTX may occur with high doses, while with low doses there is a modest decline in glomerular filtration rate (GFR) [4] . MTX is primarily cleared via the kidneys, with 80-90% excreted unchanged in urine; hence impairment in GFR will result in its sustained serum level that may induce bone marrow suppression or other toxicities [4] . Rau and Herborn [5] reported that GFR was reduced by 10% during MTX treatment in RA patients without co-medication. Seideman et al. concluded; low dose MTX can impair GFR and that should be considered especially if combined with other nephrotoxic drugs [6] .
The cornerstone for diagnosing renal disease is GFR estimation which is influenced by various factors including structural and/or functional kidney disease, patient's age, weight, and body surface area. The gold standard for GFR estimation is inulin-clearance, which is too costly and timeconsuming. In routine clinical practice, Chromium-51-ethylenediaminetetraacetic acid (51Cr-EDTA) clearance is a widely accepted and accurate substitute yet a very expensive screening tool [7] . So, both remain essentially research tools and are not used in clinical practice [8] . Thus, other isotope clearance methods were validated, employing labeled diethylenetriamine-pentaacetic acid (DTPA) [9] . The value of GFR estimation is strengthened by the fact that normal serum creatinine may not be elevated until GFR is less than 50% of normal [10] .
Till now, our knowledge of the toxicity profile of MTX is still being refined, as either new toxic effects or modifications in the behavior of some of the already known toxicities continue to come to light even after five decades of its use [11] . We aimed to evaluate the cumulative effect of MTX on GFR in RA patients with normal serum creatinine using Tc-99 m DTPA and correlate with various parameters to help boost the overall safety of MTX on renal function.
Materials and methods
The study was approved by the local ethics committee of Cairo-University scientific review board and informed consent was obtained from all subjects according to the Declaration of Helsinki; General Assembly, October 2008. It included 52 adult female RA patients fulfilling 1987 revised ACR criteria for the classification of RA [12] and divided into two groups. Group [13] at the initial diagnosis of the disease. We excluded any patient with abnormalities in blood glucose, lipid profile, uric acid, urine analysis [including microalbuminuria assay] and renal sonography, uncontrolled hypertension, cardiac or hepatic insufficiency, cigarette smoking, BMI-based obesity, present or past history of nephrotoxic drugs, and other autoimmune diseases.
The cumulative dose of MTX was estimated by multiplying the current weekly dose by number of weeks since it was initiated. BMI was calculated for all subjects and DAS28 score was used to assess disease activity [14] . Renal function was assessed by GFR-measurement using Tc-99 m-DTPA; Gates' method [15] at the point of the study time corresponding to disease duration.
Patients' categorization was performed according to the recommendations of Kidney-Dialysis Outcomes and Quality Initiative Stages [K/DOQI] into normal and chronic kidney disease (CKD) using generated GFR values [16] . The % annual GFR reduction was calculated by the following formula: % Annual GFR reduction ¼ \Base-Line GFR À GFR at the study time"=Disease duration in years Â 100
Statistics: Data were analyzed by SPSS version 14. Continuous data were presented as means ± SD, while discrete data were shown as numbers and percentages. Cross tabulation was utilized to describe the relations between variables using the contingency coefficient. Levene's test (F-test) for the equality of variances was used and t-test for testing differences between parametric data. Correlation between parametric variables was performed using Pearson's correlation coefficient. Z proportion was used to test the statistical difference between both groups regarding GFR. Significance was defined as P < 0.05 throughout.
Results
In G1 and G2, the means of disease duration were 6 ± 0.5 and 6 ± 0.4 years, DAS28 3.3 ± 0.8 and 3.8 ± 0.5 and BMI values (23.93 ± 2.62) and (22.85 ± 3.61), respectively. Patients' laboratory findings are shown in Table 1 . MTX and NSAID regimens of G1 are detailed in Table 2 . In G2, the mean of NSAID duration intake was 5.6 ± 0.8 being almost identical to that in G1 and the same implies to dosage and intake regimens.
Base-line GFR was normal in G1 [Range 95-125; 100 ± 9.5 ml/min] and G2 [Range 94-128; 99 ± 11.5 ml/ min]. At the study time in G1; GFR ranged 57-120 [75.6 ± 12.7 ml/min] being reduced in 21 (70%) patients while in G2; GFR ranged 59-115 [98.8 ± 7.1 ml/min] being reduced in 6 (27.3%) patients [ Table 3 ] with a significant difference between both groups regarding patients' number with reduced GFR [P0.007] and their GFR means [P0.003]. Annual reduction of GFR was found to be 3.3 ± 0.5% throughout the disease duration of affected cases in G1. Correlations between GFR in G1 and G2 with various disease parameters showed significant negative correlations with patients' age (r-0.396, P0.005), MTX cumulative dose (r-0.263, P0.049), duration of MTX intake (r-0.293, P0.031) and duration of NSAID intake (r-0.344, P0.014) in G1 while no significant correlations were provoked with disease duration and DAS28. In G2 no similar significant correlations were elicited regarding the same parameters.
Discussion
This study was carried out on 52 RA patients with normal serum creatinine who were divided into G1 [on MTX and NSAIDs] and G2 [only on NSAIDs]. G1 showed a high prevalence of reduced GFR at the study time [70%] compared to G2 [27.3%] with 3.3 ± 0.5% annual reduction of GFR in G1 that may suggest the slow cumulative negative effect of MTX on GFR. To our knowledge, no previous studies have reported GFR estimation using Tc-99 m DTPA in RA patients to assess such effect of MTX.
In routine clinical practice, clinicians have relied on serum creatinine to assess renal function. However, its level depends also on muscle mass since creatinine is derived from muscle creatine. It cannot therefore, in isolation, accurately reflect kidney function of an individual as it varies according to factors such as age, sex, body mass and ethnic origin. Reduced GFR can be present despite normal creatinine which may not be elevated until GFR is less than 50% of normal [9, 10] .
Creatinine clearance can be a surrogate marker of GFR since creatinine is freely filtered by the glomerulus, but is also excreted by the renal tubules in very small amounts so it overestimates GFR by 10-20%. Also, its reliability is directly dependent on properly timed and precisely collected 24-h urine sample which is a usual obstacle especially in females together with 20% day to day variation in its value [9] . Modification of Diet in Renal Disease Study Group [MDRD] and Cockcroft Gault formulas are widely used in clinical settings and are considered among the most accurate methods, however MDRD was not specifically validated for RA patients [17] and both were reported to be less accurate than radionuclide methods [9, 18] . A significant statistical difference was found between G1 and G2 as regards patients with reduced GFR and their GFR-means. Also, in G1 significant negative correlations between GFR and MTX cumulative dose and intake duration as well as NSAID were provoked. Seidman et al. [6] reported that a low dose MTX treatment may significantly impair kidney function; however they used 51Cr-EDTA for GFR estimation while we utilized Tc-99 m DTPA being comparable to the former [19] . Also, Rau and Herborn [5] reported 10% reduction in GFR during MTX treatment in RA patients without co-medication. Verstappen et al. [20] studied the toxicity of low dose MTX and reported a trend toward an association between diminished creatinine clearance and MTX. It is suggested that as MTX breaks down, there are pieces that are not soluble in acidic urine that can precipitate and accumulate, causing slow toxicity to the kidneys and renal dysfunction as tubular precipitation of such insoluble crystals can increase intra-tubular pressure; this opposes glomerular filtration pressure and can decrease GFR [21] .
Townsend [22] mentioned that NSAIDs can impair GFR while, Harirforoosh and Jamali [23] stated a relationship between their high plasma concentration and renal adverse effects, with more tendency in patients with diabetes, heart failure, renal dysfunction and elderly. In our study, both groups received NSAIDs which do not alter absorption, protein binding, distribution, half-life or elimination of MTX [24] . Weinblatt [4] reported that an increase in free MTX because of displacement from albumin by NSAIDs can occur, but this is generally of limited clinical significance with low dose MTX, because its increase is usually modest. Also, Fitzgerald and Patrono [25] reported similar findings. Thus based on the aforementioned data, MTX is the solely incriminated drug for the higher percentile of our RA patients with reduced GFR in G1 [70%]. Daoussis et al. [26] used MDRD Tc-99m diethylenetriamine pentaacetic acid (DTPA):
in 400 RA patients for GFR estimation and found no significant correlation between GFR with DAS28 score or disease duration and reported significant negative correlation with patients' age; these findings were all in agreement with ours. In this study, MTX showed a negative cumulative effect on GFR measured with Tc-99 m DTPA which is of recent critical relevance as current data have emerged indicating a strong link and cross talk between cardiovascular risk and renal dysfunction [27] . Thus awareness of such drawback; even modest must be considered in the prevention strategies for cardiovascular disease in RA patients.
In conclusion, we suggest that MTX has an adverse effect on GFR, so its prescription rates should be based on a reliable method for GFR estimation as Tc-99 m DTPA to define those likely to benefit from its dose adjustment and avoidance of those drugs with predictable adverse effects on renal function as NSAIDs.
